A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Everybody may love Raymond, but Ray Romano loves Peter Boyle
China Focus: Chinese Leadership Analyzes Economic Situation, Work
Xi Story: Agricultural Science, Technology Carry the Weight of Food Security
Xi Story: Paddling Through All Odds on Fact
Storms damage homes in Oklahoma and Kansas. But in Houston, most power is restored
Grand Canal to get refilled with water in all dried
Book on Value of Xi Jinping's Economic Thought Published
Xi Meets Representatives to 10th Conference for Friendship of Overseas Chinese Associations
Company wins court ruling to continue development of Michigan factory serving EV industry
Xi Urges Submarine Crew to Become Elite Force
Liverpool confirms Arne Slot as Jurgen Klopp's replacement
Xi Story: Paddling Through All Odds on Fact